VivoSeq
Other

Cohort Study

0

Pipeline Programs

12

Active Trials

7

Companies Involved

Cohort Study is an early-stage landscape with 0 programs across 7 companies. The most active players are Pfizer, GSK, AstraZeneca.

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

4/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

46

clinical trials

Completed17 · 37%
Unknown status15 · 33%
Recruiting6 · 13%
Not yet recruiting3 · 7%
Active, not recruiting2 · 4%
Withdrawn2 · 4%
Other1 · 2%

Trial Activity

46 trials

Long-term Safety of Danicopan: IPIG Registry-based Cohort Study
Active, not recruiting·AstraZeneca logoAstraZeneca·N/A·NCT07413679·50 enrolled
DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study
Not yet recruiting··N/A·NCT06884384·310 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)